LifeVantage (NASDAQ:LFVN) Stock Price Crosses Above 200 Day Moving Average – Should You Sell?

LifeVantage Co. (NASDAQ:LFVN) passed above its 200-day moving average during trading on Monday . The stock has a 200-day moving average of $15.57 and traded as high as $17.64. LifeVantage shares last traded at $17.04, with a volume of 153,399 shares.

Analysts Set New Price Targets

Several equities research analysts have weighed in on the company. Craig Hallum initiated coverage on LifeVantage in a report on Tuesday, January 14th. They issued a “buy” rating and a $35.00 price objective for the company. Lake Street Capital initiated coverage on shares of LifeVantage in a research report on Thursday, December 19th. They issued a “buy” rating and a $26.00 target price for the company.

LifeVantage Price Performance

The stock’s 50 day simple moving average is $19.80 and its two-hundred day simple moving average is $15.63. The firm has a market cap of $204.33 million, a P/E ratio of 29.07 and a beta of 0.74.

LifeVantage (NASDAQ:LFVN) last posted its quarterly earnings data on Wednesday, February 5th. The company reported $0.22 earnings per share for the quarter, beating analysts’ consensus estimates of $0.14 by $0.08. LifeVantage had a return on equity of 34.29% and a net margin of 3.46%.

LifeVantage Announces Dividend

The business also recently declared a quarterly dividend, which was paid on Monday, March 17th. Stockholders of record on Monday, March 3rd were given a $0.04 dividend. This represents a $0.16 annualized dividend and a dividend yield of 0.98%. The ex-dividend date was Monday, March 3rd. LifeVantage’s dividend payout ratio is presently 28.57%.

Insider Activity at LifeVantage

In other news, Director Raymond B. Greer sold 8,000 shares of the company’s stock in a transaction that occurred on Monday, February 10th. The shares were sold at an average price of $20.15, for a total value of $161,200.00. Following the transaction, the director now owns 99,288 shares in the company, valued at approximately $2,000,653.20. This represents a 7.46 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is accessible through this link. 20.65% of the stock is currently owned by insiders.

Institutional Investors Weigh In On LifeVantage

Several institutional investors and hedge funds have recently made changes to their positions in LFVN. Copeland Capital Management LLC bought a new position in LifeVantage in the 4th quarter valued at approximately $65,000. Hillsdale Investment Management Inc. lifted its holdings in shares of LifeVantage by 7.3% during the fourth quarter. Hillsdale Investment Management Inc. now owns 14,720 shares of the company’s stock valued at $258,000 after purchasing an additional 1,000 shares in the last quarter. Schonfeld Strategic Advisors LLC purchased a new stake in shares of LifeVantage during the fourth quarter valued at $282,000. OMERS ADMINISTRATION Corp bought a new stake in LifeVantage in the 4th quarter worth about $284,000. Finally, Millennium Management LLC bought a new stake in LifeVantage in the 4th quarter worth about $574,000. Institutional investors own 35.32% of the company’s stock.

LifeVantage Company Profile

LifeVantage Corporation engages in the identification, research, development, formulation, and sale of advanced nutrigenomic activators, dietary supplements, nootropics, pre- and pro-biotics, weight management, skin and hair care, bath and body, and targeted relief products. It offers Protandim, a dietary supplement; LifeVantage Omega+, a dietary supplement that combines DHA and EPA Omega-3 fatty acids, Omega-7 fatty acids, and vitamin D3; LifeVantage ProBio, a dietary supplement to support gut health; PhysIQ, a weight management system; LifeVantage IC Bright, a supplement to support eye and brain health, reduce eye fatigue and strain, supports cognitive functions, and support normal sleep patterns; Petandim for Dogs, a supplement to combat oxidative stress in dogs; and Axio, a nootropic energy drink mix.